Concerns exist that published rates of hemorrhage may not reflect real-world practice. Few patients 80 years of age
were enrolled in trials, and studies of prevalent use largely reflect a warfarin-tolerant subset. We sought to define the
tolerability of warfarin among an elderly inception cohort with atrial fibrillation.